| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 131 | 147 | 163 | 150 | 155 | 167 | 230 | 213 | 199 | 198 | 231 | 228 | 641 | 237 | 254 | 273 | 284 | 279 | 290 | 317 | 302 | 297 | 352 | 358 | 363 | 323 | 351 | 362 | 388 | 342 | 339 | 378 | 368 | 334 | 356 | 337 | 365 | 393 | 373 | 397 | 403 | 445 |
| Expenses | 130 | 128 | 137 | 144 | 143 | 157 | 208 | 201 | 176 | 178 | 179 | 210 | 213 | 213 | 224 | 235 | 243 | 240 | 247 | 266 | 256 | 250 | 300 | 291 | 319 | 300 | 331 | 322 | 350 | 342 | 335 | 365 | 432 | 365 | 331 | 307 | 334 | 348 | 334 | 357 | 356 | 391 |
| EBITDA | 1 | 19 | 26 | 6 | 12 | 10 | 22 | 12 | 22 | 20 | 52 | 19 | 428 | 24 | 30 | 38 | 41 | 40 | 43 | 51 | 47 | 47 | 52 | 67 | 45 | 23 | 20 | 40 | 37 | -0 | 4 | 13 | -63 | -31 | 25 | 30 | 32 | 45 | 39 | 40 | 48 | 55 |
| Operating Profit % | 0 % | 12 % | 13 % | 2 % | 6 % | 5 % | 8 % | 3 % | 11 % | 8 % | 10 % | 7 % | 8 % | 10 % | 11 % | 13 % | 14 % | 14 % | 13 % | 16 % | 15 % | 15 % | 14 % | 18 % | 12 % | 6 % | 6 % | 10 % | 9 % | -0 % | 1 % | 3 % | -18 % | -10 % | 4 % | 7 % | 8 % | 11 % | 9 % | 9 % | 11 % | 12 % |
| Depreciation | 10 | 9 | 9 | 11 | 16 | 13 | 16 | 13 | 10 | 10 | 10 | 12 | 10 | 10 | 10 | 11 | 11 | 12 | 13 | 13 | 13 | 13 | 13 | 12 | 13 | 13 | 13 | 13 | 13 | 14 | 13 | 14 | 15 | 14 | 15 | 16 | 17 | 16 | 17 | 17 | 16 | 15 |
| Interest | 11 | 11 | 8 | 8 | 10 | 8 | 9 | 8 | 7 | 6 | 7 | 10 | 10 | 8 | 8 | 8 | 9 | 9 | 8 | 10 | 9 | 8 | 7 | 6 | 3 | 3 | 3 | 4 | 6 | 7 | 8 | 10 | 11 | 11 | 13 | 13 | 12 | 16 | 14 | 15 | 15 | 14 |
| Profit Before Tax | -16 | 1 | 8 | -8 | -15 | -11 | -2 | -9 | 6 | 4 | 34 | -3 | 409 | 7 | 12 | 18 | 22 | 19 | 23 | 28 | 24 | 26 | 32 | 50 | 29 | 7 | 4 | 24 | 18 | -21 | -18 | -10 | -89 | -56 | -3 | 2 | 3 | 12 | 8 | 8 | 16 | 26 |
| Tax | 3 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | -5 | 2 | 4 | 4 | 4 | 2 | -3 | 3 | 0 | 4 | -2 | 4 | 6 | 7 | 8 | 12 | 6 | 5 | -10 | 5 | 8 | -6 | -13 | -0 | 4 | -21 | 4 | -9 | 1 | 3 | 2 | 2 | 6 | 8 |
| Net Profit | -19 | -0 | 7 | -8 | -15 | -12 | -4 | -11 | 11 | 2 | 31 | -7 | 405 | 5 | 16 | 16 | 21 | 15 | 25 | 24 | 18 | 19 | 24 | 38 | 24 | 3 | 14 | 19 | 10 | -15 | -4 | -10 | -92 | -35 | -7 | 11 | 1 | 9 | 6 | 7 | 10 | 18 |
| EPS in ₹ | -7.09 | 0.01 | 1.27 | -0.50 | -0.55 | -0.43 | -0.22 | -0.21 | 0.28 | 0.09 | 1.21 | -0.39 | 0.14 | 0.14 | 0.63 | 0.54 | 0.71 | 0.47 | 0.88 | 0.83 | 0.69 | 0.93 | 0.86 | 1.45 | 0.84 | 0.04 | 0.58 | 0.69 | 0.36 | -0.60 | -0.15 | -0.36 | -3.77 | -1.40 | -0.34 | 0.33 | -0.04 | 0.26 | 0.11 | 0.14 | 0.37 | 0.57 |
Sequent Scientific
Sequent Scientific
183.81
+6.69
(3.78%)
Market Cap
4,600.86 Cr
EPS
0.88
PE Ratio
146.53
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
240.70
52 Week Low
117.35
PB Ratio
6.30
Debt to Equity
0.71
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
The proposed merger between Carlyle portfolio companies Sequent Scientific and Viyash Life Sciences received approval from 99.98% of Sequent's public shareholders on August 30. The ₹8,000-crore merger will combine Sequent, a listed animal health company, with privately-held Viyash Life Sciences, which operates in human health. Hari Babu Bodepudi, founder of Viyash Life Sciences and former global COO of Mylan, will serve as group CEO-designate of the combined entity and become the second-largest shareholder with under 10% stake after Carlyle. The merged company will operate 15-16 manufacturing sites, with Viyash contributing 9 sites to provide backward integration capabilities for Sequent. The combination aims to create synergies by allowing Sequent to tap into generics opportunities in animal health products while Viyash can leverage Sequent's relationships with innovator companies in the companion animal segment.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,593.60 | #1 3,82,358.02 | 33.10 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 39.45 | |
6,009.00 | 1,59,520.07 | 70.63 | 9,712.00 | 18.67 | 2,191 | 26.74 | 43.85 | |
1,553.40 | 1,25,469.33 | 23.63 | 28,409.50 | 7.12 | 5,291 | 9.88 | 57.67 | |
3,579.10 | 1,21,133.01 | 60.27 | 11,539.40 | 6.99 | 1,911 | 19.91 | 51.53 | |
1,268.10 | 1,05,831.96 | #1 18.41 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.40 | |
2,550.60 | 1,05,270.59 | 56.03 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 55.83 | |
1,013.85 | 1,02,017.03 | 21.84 | 23,511.00 | 18.55 | 4,615 | 2.60 | 60.44 | |
1,943.90 | 88,777.03 | 23.95 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 50.97 | |
31,150.00 | 66,191.58 | 47.11 | 6,684.70 | 9.64 | 1,414 | 11.55 | 45.41 | |
5,333.50 | 63,769.99 | 27.89 | 13,458.30 | 3.70 | 2,216 | 21.39 | 57.64 |
Forecast
Actual
Growth Rate
Revenue Growth
13.43 %
Net Income Growth
-209.12 %
Cash Flow Change
172.42 %
ROE
-200.96 %
ROCE
-1,430.56 %
EBITDA Margin (Avg.)
115.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 908 | 1,528 | 1,905 | 1,343 | 1,388 | 1,463 | 1,393 | 1,451 | 1,529 | 1,540 | 1,602 |
| Fixed Assets | 474 | 587 | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 | 586 |
| Current Assets | 310 | 491 | 728 | 538 | 600 | 704 | 714 | 783 | 780 | 811 | 873 |
| Capital Work in Progress | 39 | 24 | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 16 | 16 |
| Investments | 1 | 428 | 428 | 239 | 180 | 172 | 83 | 38 | 0 | 4 | 0 |
| Other Assets | 394 | 491 | 760 | 610 | 687 | 701 | 744 | 837 | 869 | 929 | 1,000 |
| Total Liabilities | 908 | 1,528 | 1,905 | 1,343 | 1,388 | 1,463 | 1,393 | 1,451 | 1,529 | 1,540 | 1,602 |
| Current Liabilities | 406 | 290 | 664 | 431 | 434 | 495 | 460 | 512 | 559 | 627 | 505 |
| Non Current Liabilities | 264 | 290 | 247 | 227 | 207 | 236 | 156 | 199 | 221 | 200 | 327 |
| Total Equity | 238 | 948 | 994 | 685 | 747 | 732 | 776 | 740 | 749 | 713 | 770 |
| Reserve & Surplus | 32 | 885 | 928 | 599 | 657 | 637 | 678 | 633 | 649 | 607 | 654 |
| Share Capital | 31 | 48 | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 | 50 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | -2 | 24 | -5 | 28 | 0 | -14 | 4 | -16 | 23 | -2 |
| Investing Activities | -157 | -311 | -116 | 7 | -68 | -72 | 10 | -94 | -65 | -6 | -25 |
| Operating Activities | -24 | -0 | -7 | 45 | 116 | 115 | 115 | 31 | 17 | 31 | 83 |
| Financing Activities | 179 | 309 | 147 | -57 | -20 | -43 | -139 | 67 | 32 | -1 | -61 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 53.86 % | 53.86 % | 53.52 % | 53.02 % | 53.02 % | 52.79 % | 52.79 % | 52.79 % | 52.79 % | 52.79 % | 52.79 % | 52.79 % | 52.79 % | 52.78 % | 52.76 % | 52.61 % | 52.61 % | 52.61 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 6.03 % | 0.00 % | 6.16 % | 5.70 % | 6.45 % | 6.10 % | 6.05 % | 6.15 % |
| DIIs | 2.68 % | 2.11 % | 1.49 % | 0.51 % | 0.30 % | 0.29 % | 1.66 % | 2.81 % | 2.92 % | 2.92 % | 3.23 % | 5.02 % | 7.59 % | 8.06 % | 9.99 % | 12.02 % | 12.82 % | 12.98 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 19.28 % | 19.04 % | 19.57 % | 26.31 % | 27.64 % | 28.20 % | 27.92 % | 28.61 % | 29.03 % | 28.85 % | 29.25 % | 25.11 % | 24.43 % | 25.01 % | 24.00 % | 23.82 % | 23.43 % | 22.37 % |
| Others | 24.19 % | 25.00 % | 25.42 % | 20.17 % | 19.04 % | 18.72 % | 17.63 % | 15.80 % | 15.26 % | 15.44 % | 8.70 % | 17.08 % | 9.02 % | 8.45 % | 6.80 % | 5.46 % | 5.09 % | 5.89 % |
| No of Share Holders | 0 | 62,318 | 86,848 | 1,24,014 | 1,67,812 | 1,91,092 | 1,97,176 | 1,93,954 | 1,96,231 | 1,87,474 | 1,84,521 | 1,72,853 | 1,66,593 | 1,63,693 | 1,54,603 | 1,62,574 | 1,58,152 | 1,47,320 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.2 | 0.2 | 0.00 | 0.5 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.28 | 0.26 | 0.00 | 0.37 | 0.00 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 10 Sept 2021 |  Dividend | ₹ 0.50 /share | 08 Sept 2021 | 322.30 | 236.15 |
| 17 Sept 2024 |  Annual General Meeting | NA | 17 Sept 2024 | 165.50 | 178.10 |
| 13 Nov 2024 |  Quarterly Result Announcement | NA | 13 Nov 2024 | 211.07 | 202.90 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 160.00 | 156.65 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 153.25 | 177.30 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 175.85 | 175.00 |
| 08 Aug 2025 | Annual General Meeting | NA | 08 Aug 2025 | 181.65 | 175.00 |
| 26 Aug 2025 |  Extraordinary General Meeting | NA | 26 Aug 2025 | 175.15 | 174.65 |
| 30 Aug 2025 | Extraordinary General Meeting | NA | 30 Aug 2025 | 173.85 | 169.45 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Directorate
2 days ago
2 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On September 05 20252 days ago
2 days agoShareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting7 days ago
7 days agoShareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting7 days ago
7 days agoShareholder Meeting / Postal Ballot-Scrutinizer"s Report7 days ago
7 days agoShareholder Meeting / Postal Ballot-Scrutinizer"s Report7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Aug 09, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Aug 08, 2025Unaudited Standalone & Consolidated Financial Results For The Quarter Ended June 30 2025Aug 08, 2025
Aug 08, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Friday August 08 2025 Along With Unaudited Standalone & Consolidated Financial Results For The Quarter Ended June 30 2025Aug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 29, 2025
Jul 29, 2025Disclosure Under Regulations 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations).Jul 28, 2025
Jul 28, 2025Announcement Under Regulation 30 -UpdateJul 18, 2025
Jul 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Jul 17, 2025Letter To The Shareholders - Annual Report F.Y. 2024-25Jul 16, 2025
Jul 16, 2025Reg. 34 (1) Annual Report.Jul 16, 2025
Jul 16, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 16, 2025
Jul 16, 2025Notice Of 40Th Annual General Meeting Scheduled On August 08 2025.Jul 16, 2025
Jul 16, 2025Reg. 34 (1) Annual Report.Jul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 16, 2025
Jul 16, 2025Re-Appointment Of Non-Executive Independent Directors.Jul 14, 2025
Jul 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 26, 2025
Jun 26, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 18, 2025
Jun 18, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 29, 2025
May 29, 2025Receipt Of Observation Letters With No Adverse Observations From BSE Limited And No Objection From The National Stock Exchange Of India Limited On The Composite Scheme Of
AmalgamationMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
May 20, 2025Announcements Under Reg 30May 20, 2025
May 20, 2025Appointment Of M/S BMP & Co. LLP As Secretarial AuditorMay 20, 2025
May 20, 2025ResultsMay 20, 2025
May 20, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 20 May 2025May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 08, 2025
May 08, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Apr 30, 2025
Apr 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 24, 2025
Apr 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Apr 08, 2025Technical Indicators
RSI(14)
Neutral 61.07
ATR(14)
Volatile 5.59
STOCH(9,6)
Neutral 51.39
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 1.15
ADX(14)
Weak Trend 12.31
UO(9)
Bearish 52.21
ROC(12)
Uptrend And Accelerating 4.32
WillR(14)
Overbought -7.84
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Quant Small Cap Fund Direct Plan-Growth | 0.00% | -22502050 | -1.31% | -1.46% | |
| Quant Healthcare Fund Direct - Growth | 0.00% | -1477126 | -6.21% | -6.69% | |
 UTI Healthcare Fund Direct-Growth | 0.00% | -871145 | -1.31% | -1.53% | |
 Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth | 0.00% | -399498 | -0.26% | -0.29% | |
 Groww Nifty Total Market Index Fund Direct - Growth | 0.00% | -1864 | -0.01% | -0.01% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.00% | -1642 | -0.15% | -0.17% | |
 Angel One Nifty Total Market Index Fund Direct - Growth | 0.00% | -262 | -0.01% | -0.01% | |
 Mirae Asset Nifty Total Market Index Fund Direct-Growth | 0.00% | -260 | -0.01% | -0.01% | |
| Bandhan Nifty Total Market Index Fund Direct-Growth | 0.00% | -236 | -0.01% | -0.01% | |
 ITI Pharma and Healthcare Fund Direct - Growth | 0.00% | 0 | 0.00% | 0.00% | |
| ITI ELSS Tax Saver Fund Direct - Growth | 0.00% | 0 | 0.00% | 0.00% | |
 Samco Multi Cap Fund Direct-Growth | 0.00% | 0 | 0.00% | 0.00% | |
 WhiteOak Capital Pharma and Healthcare Fund Direct - Growth | 0.00% | 0 | 0.00% | 0.00% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
